US › Healthcare

Werewolf Therapeutics Inc (HOWL)

US · Healthcare · Biotechnology

$0.96+4.79%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$21.0M

Net profit

$3.7M

EPS

$0.08

EPS estimate

$-0.28

Net margin

17.5%

EPS came in at 0.08 against a street estimate of -0.28 — a beat of 128.6%.

Key statistics

Market cap

$47.7M

Forward P/E

0.0

P/B

2.94

Book value

$0.34

EPS (TTM)

$-0.73

52-week high

$2.38

52-week low

$0.27

50-day MA

$0.56

200-day MA

$0.65

Beta

0.51

Analyst view

Analysts rate Werewolf Therapeutics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $7.00.

Shareholding

Insiders

1.40%

Institutions

29.09%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	13.75%
Vanguard Capital Management, LLC	2.51%
Lynx1 Capital Management, LP	1.35%
Sphera Funds Management Ltd.	1.29%
DC Funds, LP	1.21%
Renaissance Technologies Corp	1.06%
Geode Capital Management, LLC	0.80%
Verdad Advisers, LP	0.72%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Werewolf Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.